US FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive NMIBC

IBRX•2026-10-14

The US FDA approved nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer on Oct. 14, 2026, and expanded its indication to high-grade papillary-only NMIBC. The recommended induction dose is 400 mcg with BCG weekly for six weeks.

US FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive NMIBC

1. FDA approval and dose

Related News

Liquidia surges as United Therapeutics settlement removes key litigation risk

Nasdaq trade halt: volatility trading pause at 10:19 a.m.

US cuts Obamacare subsidies for 189,000 with duplicate coverage

Non-competitive bids for U.S. 17-week bills

Chevron sees first gas from Aseng in 2028 as Equatorial Guinea seeks to stem output decline